Recombinant MS4A1 (Ocrelizumab Biosimilar) anticorps

N° du produit ABIN7487883

Cet anticorps Mammalian Cells Monoclonal détecte spécifiquement MS4A1 (Ocrelizumab Biosimilar) dans ELISA. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant MS4A1 (Ocrelizumab Biosimilar) anticorps (ABIN7487883)

Antigène: MS4A1 (Ocrelizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp MS4A1 (Ocrelizumab Biosimilar) est non-conjugé

Application: ELISA

Classe de qualité: Research Grade

Détail du produit anti-MS4A1 (Ocrelizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb

Attributs du produit: Antibody Type: IgG1-nd

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: -80 °C

Stockage commentaire: store at -80°C

Détails sur MS4A1 (Ocrelizumab Biosimilar)

Antigène: MS4A1 (Ocrelizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: 2H7
Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission.

Numéro CAS: 637334-45-3